Back to search

Article

Comprehensive Biomarker and Genomic Analysis Identifies p53 Status as the Major Determinant of Response to MDM2 Inhibitors in Chronic Lymphocytic Leukemia.

2007-11-16

Abstract excerpt

Abstract To understand determinants of sensitivity or resistance to MDM2 inhibitor therapy in chronic lymphocytic leukemia (CLL), we comprehensively analyzed highly pure CD19+ cells derived from 106 CLL patients for response to the MDM2 inhibitors MI-63 and Nutlin3 ex vivo and correlated these responses with clinically important biomarkers, including hierarchical FISH, IgVH-mutations and ZAP70 expression. P53 exon...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
98b01c58-466d-523e-b354-37a4216b0fb5
DOI
10.1182/blood.v110.11.224.224
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Comprehensive Biomarker and Genomic Analysis Identifies p53 Status as the Major Determinant of Response to MDM2 Inhibitors in Chronic Lymphocytic Leukemia.DOI 10.1182/blood.v110.11.224.224
Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.Semantic proximity
The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to MDM2 inhibitor-mediated apoptosis.Semantic proximity
The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatmentSemantic proximity
An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness.Semantic proximity
Complex TP53 Alterations with del(17p) and del(13q) in Chronic Lymphocytic Leukemia: Clinical Implications from a Case-Based Review.Semantic proximity
An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted TherapySemantic proximity
SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia.Semantic proximity
The clinical implications of gene mutations in chronic lymphocytic leukaemia.Semantic proximity
Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlationsSemantic proximity
The Biology of Chronic Lymphocytic Leukemia: Diagnostic and Prognostic Implications.Semantic proximity
RNA-Sequencing Reveals Candidate Genes/Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic LeukemiaSemantic proximity
Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia.Semantic proximity
Select a neighboring publication to make it the new centre.